EP1203 Cytoreductive surgery for tubo-ovarian carcinoma - a study of MDT decision-making for primary vs NACT-interval surgery

2019 ◽  
Author(s):  
R Daly ◽  
Y Shahabuddin ◽  
C Thompson ◽  
N Gleeson
Keyword(s):  
Decision Making ◽  
Ovarian Carcinoma ◽  
Cytoreductive Surgery ◽  
Interval Surgery

Cardiac index assessment using bioreactance in patients undergoing cytoreductive surgery in ovarian carcinoma

2013 ◽  
Vol 27 (6) ◽  
pp. 621-627 ◽  
Author(s):  
David Kober ◽  
Constantin Trepte ◽  
Martin Petzoldt ◽  
Rainer Nitzschke ◽  
Lena Herich ◽  
...  
Keyword(s):  
Cardiac Index ◽  
Ovarian Carcinoma ◽  
Cytoreductive Surgery

Upfront cytoreductive surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer in Indian patients

2021 ◽  
Author(s):  
Mukur Dipi Ray ◽  
Suryanarayana S.V. Deo ◽  
Lalit Kumar ◽  
Manish Kumar Gaur
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
Cytoreductive Surgery ◽  
Advanced Ovarian Cancer ◽  
Advanced Stages ◽  
Selection For ◽  
Selection Of Patients ◽  
Selection Of

In cases of ovarian carcinoma, primary cytoreductive surgery (CRS) is the standard treatment up to stage IIIB, but patient selection for neoadjuvant chemotherapy (NACT) in selected cases is controversial. A total of 200 patients with advanced ovarian cancer were analyzed retrospectively, according to specific selection criteria. Primary CRS was performed in 95 patients (47.5%) and interval CRS after 3–6 cycles of NACT was performed in 105 patients (52.5%). After median follow-up of 35 months, 5-year overall survival was 53.7% in the upfront CRS group and 42.2% in the NACT group. Primary CRS is the standard in advanced stages of ovarian carcinoma, but in certain subset of patients, NACT is preferred. Identifying that group is challenging but feasible. Proper selection of patients is key to successful outcomes.

Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making

2020 ◽  
Vol 156 (3) ◽  
pp. 517-522 ◽  
Author(s):  
Soledad Jorge ◽  
Andrew S. McFaddin ◽  
Kemi M. Doll ◽  
Kathryn P. Pennington ◽  
Barbara M. Norquist ◽  
...  
Keyword(s):  
Decision Making ◽  
Ovarian Carcinoma ◽  
Mutation Rate ◽  
Clinical Decision Making ◽  
Clinical Decision

A case of protrusion of an intraperitoneal chemotherapy catheter through rectum

2005 ◽  
Vol 15 (1) ◽  
pp. 171-174 ◽  
Author(s):  
Y. Bilsel ◽  
E. Balik ◽  
D. Bugra ◽  
S. Yamaner ◽  
A. Akyuz
Keyword(s):  
Ovarian Carcinoma ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery

Bowel penetration of an intraperitoneal catheter occurred in a patient who had received a course of uncomplicated intraperitoneal chemotherapy for a persistent ovarian carcinoma. One month after the termination of chemotherapy, she presented with protrusion of a catheter through anus. At operation, the catheter was removed, the rectum was repaired primarily, and a cytoreductive surgery was performed.

Sign in / Sign up

Export Citation Format

Share Document